As per the Delveinsight, total Nontuberculous mycobacterial (NTM) infection prevalence in the 7MM (the United States, EU5 (the United Kingdom, Germany, France, Italy and Spain), and Japan) is expected to increase with a CAGR of 0.6% by 2030.
The Nontuberculous mycobacterial infection prevalence in the United States is the highest among the seven major markets, followed by Japan. While in the European-5 countries, Germany accounted for the highest NTM infection prevalent population followed by France and the UK, with Spain accounting for the lowest NTM infection prevalent population.
The Nontuberculous Mycobacterial Infection Market in the seven major markets is expected to increase at a CAGR of 6.6% for the study period i.e. 2017–2030.
The Nontuberculous Mycobacterial Infection Market Drivers-
-
Increasing demand of therapeutic products
-
Impending opportunities in the market
-
Increasing prevalence, and
-
Increasing spending on branded drugs
The key companies in the Nontuberculous mycobacterial (NTM) infection Market include Insmed Incorporated, RedHill Biopharma Ltd., Novoteris, Savara Inc., Beyond Air™ and others.
For more detailed information on Nontuberculous Mycobacterial (NTM) Infection market, visit: https://www.delveinsight.com/blog/nontuberculous-mycobacterial-infection-market-size/